Arcangeli G, Cividalli A, Nervi C, Creton G, Lovisolo G, Mauro F
Int J Radiat Oncol Biol Phys. 1983 Aug;9(8):1125-34. doi: 10.1016/0360-3016(83)90170-0.
Tumor control and therapeutic gain have been evaluated in a series of studies on patients with multiple lesions employing different protocols of combined radiotherapy (RT) and local external hyperthermia (HT). Tumor response has been evaluated during a follow-up ranging 6 to 18 months. Therapeutic enhancement factor (TEF) was defined as the ratio of thermal enhancement (TE) of tumors to TE of skin, where TE was clinically evaluated as the ratio of percent response (i.e., complete tumor clearance and moist desquamation, respectively) after combined modality to percent response after RT alone. Local tumor control was constantly better in lesions treated with any combined modalities in comparison with RT alone. The use of high RT dose per fraction appeared to increase tumor control only in the combined modalities groups, the immediate (so called "simultaneous") schedule (HT at 42.5 degrees C/45 min, applied immediately after each RT fraction, twice a week) being more effective than the delayed (so called "sequential") treatment (HT at 42.5 degrees C/45 min, delivered 4 h after each RT fraction, twice a week). The combination of high RT dose per fraction with high temperature HT (45 degrees C for 30 min) achieved the best tumor control. No increased radiation skin reaction was observed when a conventional fraction size of RT was used (3 daily fractions of 1.5-2 Gy, 4 h interval between fractions) in association with HT (42.5 degrees C/45 min, every other day, immediately after the second daily RT fraction). A remarkable enhancement of skin reaction was observed, however, when using high RT doses per fraction in association with 42.5 degrees C HT, especially with the immediate treatment schedule. No enhancement of skin reaction was obtained after high RT doses per fractions and 45 degrees C HT because an active skin cooling by means of circulating cold water was used in these cases. Consequently, a good TEF (1.58) was obtained when conventional RT doses per fraction were used in association with 42.5 degrees C HT. TEF values of 1.40 and 1.15 were observed when high RT doses per fraction were employed in association with the delayed and immediate 42.5 degrees C HT, respectively. HT at 45 degrees C can be safely employed only when tumors can be heated selectively or at least preferentially in comparison with normal tissue; in the lesions treated with such a schedule a TEF of 2.10 was obtained.
在一系列针对患有多处病灶的患者的研究中,采用不同的放疗(RT)与局部体外热疗(HT)联合方案,对肿瘤控制和治疗增益进行了评估。在6至18个月的随访期间评估了肿瘤反应。治疗增强因子(TEF)定义为肿瘤的热增强(TE)与皮肤的TE之比,其中TE在临床上评估为联合治疗后反应百分比(即分别为肿瘤完全清除和湿性脱皮)与单纯放疗后反应百分比之比。与单纯放疗相比,任何联合治疗方式治疗的病灶局部肿瘤控制始终更好。每分次使用高放疗剂量似乎仅在联合治疗组中增加了肿瘤控制,即时(所谓“同步”)方案(42.5℃/45分钟的热疗,在每次放疗分次后立即应用,每周两次)比延迟(所谓“序贯”)治疗(42.5℃/45分钟的热疗,在每次放疗分次后4小时进行,每周两次)更有效。每分次高放疗剂量与高温热疗(45℃持续30分钟)的联合实现了最佳的肿瘤控制。当使用常规放疗分次大小(每天3次,每次1.5 - 2Gy,分次间隔4小时)并联合热疗(42.5℃/45分钟,隔天,在第二次每日放疗分次后立即进行)时,未观察到放射性皮肤反应增加。然而,当每分次使用高放疗剂量并联合42.5℃热疗时,尤其是即时治疗方案,观察到皮肤反应显著增强。在每分次高放疗剂量和45℃热疗后未获得皮肤反应增强,因为在这些情况下采用了通过循环冷水进行的主动皮肤冷却。因此,当每分次使用常规放疗剂量并联合42.5℃热疗时,获得了良好的TEF(1.58)。当每分次使用高放疗剂量并联合延迟和即时42.5℃热疗时,分别观察到TEF值为1.40和1.15。仅当与正常组织相比肿瘤能够被选择性地或至少优先地加热时,才可以安全地采用45℃热疗;在采用这种方案治疗的病灶中,获得了2.10的TEF。